In the sterile hallways of orthopedic conferences, “Level 1 Evidence” is treated like the holy grail. Sales reps carry tablets loaded with peer-reviewed reprints. VAC (Value Analysis Committee) dossiers are thick with clinical registries. Everyone claims to be looking for the “better” implant.
But look at the data on the data: A study in Pediatric Orthopedic Surgery found that while surgeons value science, less than 18% of clinical decisions were actually attributed to scientific studies.
The reason is simple: Everyone knows the game is rigged.
This is the era of Clinical Data Theatre, a high-stakes performance where the script is written by whoever is funding the study.
1. The Gerrymandered Endpoint
The dirty secret of orthopedic research is that “success” is a flexible term. If you are a manufacturer trying to prove your new hip stem is superior, you don’t pick an endpoint that’s hard to hit—you gerrymander the criteria.
Need to show “superiority” over a cheaper competitor? Don’t look at 10-year survivorship (where everyone is the same). Instead, choose a specific, high-sensitivity Patient Reported Outcome Measure (PROM) at the 6-week mark. If you narrow the window and squint at the patient selection, you can turn a statistically insignificant “maybe” into a “clinically significant” breakthrough.
Conversely, if a hospital VAC committee wants to block an expensive new technology, they can gerrymander the data in the opposite direction. By selecting high-risk, multi-morbid patients and focusing strictly on “readmission rates” within a 30-day window, they can make even the most innovative device look like a liability.
In Clinical Data Theatre, the “Truth” is just a byproduct of where you draw the finish line.
2. The Surgeon: “I need data (to justify my habit)”
For a surgeon, switching systems is a massive cognitive load. They have “muscle memory” with specific tools. When a new company approaches them, the surgeon asks for clinical data as a defensive measure.
However, if the data is spectacular but the instruments are clunky, the surgeon won’t switch. If the data is clearly “gerrymandered”—using a patient population that looks nothing like the surgeon’s actual practice—it provides a convenient excuse to stay with the incumbent. Data isn’t a bridge to a new product; it’s a moat to protect the status quo.
3. The VAC Committee: The Illusion of “Value”
Hospital Value Analysis Committees are the ultimate stage for this performance. They demand a “clinical cross-walk” to prove a new device is better than the cheaper one.
But because any study can be engineered to favor its sponsor, the VAC committee is often staring at two conflicting studies: one from the vendor showing 99% satisfaction, and one from an internal pilot showing no difference. When data can be bent to serve any master, data becomes a wash. At that point, the theatre ends and the “auction” begins. The committee uses the “conflicting evidence” as a smoke screen to ignore the science entirely and buy based on the lowest price-point.
4. The Real Decision Makers: The “Three S’s”
If data is a malleable performance, what actually drives the $50 billion orthopedic market?
- Support: The sales rep is an unpaid member of the surgical team. If the rep knows the surgeon’s preferences and prevents “tray anxiety,” they are more valuable than a study with a gerrymandered p-value.
- Simplicity: OR efficiency is the only metric that rivals the implant cost. A system that saves 12 minutes of “under-the-lights” time wins every time, regardless of what the “selected patient” data says.
- Spreadsheets: In a world of “bundled payments,” the hospital CFO cares about the “construct cost.” If the clinical data was generated in a “cherry-picked” study of 30-year-old athletes, the CFO knows it won’t apply to their 75-year-old Medicare population.
Conclusion: Closing the Curtain
We will continue to fund registries and publish papers because the language of orthopedics is clinical. But we must stop pretending that these studies are objective truths.
Clinical Data Theatre is a necessary ritual to maintain the prestige of the industry. But until we stop gerrymandering endpoints and cherry-picking patients, the “buying decision” will continue to happen in the back of the OR, where the only data point that truly matters is: “Does it work in my hands, and what is the price?”
In theory, orthopedics is an evidence-based discipline. In practice, it is a relationship-driven, commodity-managed, and habit-based market. * The Demand: Regulatory agencies (FDA/MDR) require data for safety; VAC committees require data to justify “value”; and surgeons require data to maintain their professional identity as “scientists.”
- The Reality: Procurement decisions are dominated by price-point parity and supply chain consolidation. Surgeon decisions are dominated by instrumentation “feel,” switching costs (time), and loyalty to the sales representative who ensures the OR runs smoothly.
- The “Theatre”: Clinical data acts as a “ticket to entry” or a post-hoc justification for a decision already made based on economics or personal preference.
Article: Clinical Data Theatre
Why Orthopedics Craves Evidence but Buys on Gut and Gross Margin
In the sterile hallways of orthopedic conferences, “Level 1 Evidence” is the holy grail. Sales reps carry tablets loaded with peer-reviewed reprints. VAC (Value Analysis Committee) dossiers are thick with clinical registries. Everyone claims to be looking for the “better” implant.
But look at the data on the data: A study in Pediatric Orthopedic Surgery found that while surgeons value science, less than 18% of clinical decisions were actually attributed to scientific studies. The rest? “First principles” and “anecdote.”
This is the era of Clinical Data Theatre. It is a high-stakes performance where everyone pretends the spreadsheet is secondary to the science, while the science is actually secondary to the relationship.
1. The Surgeon: “I need data (to justify my habit)”
For a surgeon, switching a hip or knee system is a massive cognitive and operational load. They have “muscle memory” with specific tools. When a new company approaches them, the surgeon asks for clinical data.
However, if the data is spectacular but the instruments are clunky, the surgeon won’t switch. Conversely, if the instruments are great and the rep is a rockstar, “good enough” data is suddenly sufficient. In this stage of the theatre, clinical data is used as a polite barrier to keep new reps at bay, or a shield to defend their preferred (and often more expensive) brand to the hospital board.
2. The VAC Committee: The Illusion of “Value”
Hospital Value Analysis Committees are the ultimate stage for this performance. They demand a “clinical clinical cross-walk” to prove a new device is better than the incumbent.
But orthopedics has hit a “plateau of excellence.” Most modern implants from major players have 10-to-15-year survivorship rates exceeding 95%. When clinical outcomes are statistically identical, data becomes a wash. At that point, the “theatre” ends and the “auction” begins. The committee uses the lack of superior data to force the vendor into a “commodity” price bracket.
3. The Regulatory Agency: The Barrier, Not the Buyer
Regulatory bodies (like the FDA or the EU’s MDR) are the only ones who truly must have the data. But their bar is “safety and efficacy,” not “commercial superiority.” Once a device clears the regulatory hurdle, its clinical data has served its primary purpose. It is now a legal document, not a sales tool.
4. The Real Decision Makers: The “Three S’s”
If data isn’t moving the needle, what is?
- Support: The sales rep is an unpaid member of the surgical team. If the rep knows the surgeon’s preferences and prevents “tray anxiety,” they are more valuable than a 5% improvement in a clinical study.
- Simplicity: OR efficiency is the only metric that rivals the implant cost. A system that saves 10 minutes of “under-the-lights” time wins over a system with a slightly better coating but 15 extra steps.
- Spreadsheets: In a world of “bundled payments,” the hospital CFO cares about the “construct cost.” If the clinical data doesn’t prove the device will prevent a $30,000 revision in the next 90 days, the cheaper screw wins every time.
Conclusion: Closing the Curtain
We will continue to fund registries and publish papers because the language of orthopedics is clinical. But we must stop pretending that a p-value is a closing tool.
Clinical Data Theatre is necessary to maintain the prestige of the industry, but the “buying decision” happens in the back of the OR, in the sterile processing department, and in the CFO’s office—places where the “theatre” of science rarely gets a standing ovation.